Shares of Palatin Technologies, Inc. (OTCMKTS:PTNT – Get Free Report) crossed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $10.88 and traded as high as $26.87. Palatin Technologies shares last traded at $26.87, with a volume of 76 shares.
Palatin Technologies Stock Performance
The stock has a market capitalization of $26.52 million, a P/E ratio of -17.59 and a beta of 0.75. The stock’s fifty day moving average price is $20.04 and its two-hundred day moving average price is $11.04.
Palatin Technologies Company Profile
Palatin Technologies, Inc, a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that is in Phase 2 clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease, which is in Phase 3 clinical trial; and melanocortin peptides for diabetic retinopathy.
Featured Articles
- Five stocks we like better than Palatin Technologies
- Aehr Spikes on New Order, But Has Stock Gotten Ahead of Itself?
- Rackspace’s AI Land Grab: Plugging Into the Next Compute Boom
- Satellogic Is Tiny But Its Revenue Growth Is Hard to Ignore
- Why Kroger’s Pullback Could Be a Gift for Patient Investors
Receive News & Ratings for Palatin Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palatin Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
